SBSamuel M. Behar

Samuel M. Behar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Samuel M. Behar has a total of 691 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Human memory CD4 + T cells recognize non-infected macrophage bystanders exposed to Mycobacterium tuberculosis -infected cells

    by Vinicius G. Suzart, Robert Schauner, Scott M. Reba, Daniel P. Gail, Gwendolyn Swarbrick, David M. Lewinsohn, Deborah A. Lewinsohn, Bianca Lepe, Bryan D. Bryson, Samuel M. Behar, et al.

    Control of Mycobacterium tuberculosis (Mtb) infection requires CD4 + T cell recognition of infected macrophages. However, T cells also colocalize with non-infected macrophages in granulomas. We investigated whether these bystander macrophages present Mtb antigens and shape human CD4 + T cell responses. Using ex vivo co-culture systems, non-infected monocyte-derived macrophages (MDMs) were exposed to Mtb-infected MDMs or infection-conditioned supernatants before co-incubation with autologous memory CD4 + T cells from individuals with latent Mtb infection (LTBI). Bystander macrophages activated memory CD4 + T cells through MHC-II-dependent antigen presentation. Single-cell T cell receptor (TCR) sequencing and TCR-transduced reporter cell lines identified Mtb-specific clonotypes recognizing both infected and bystander macrophages, as well as clonotypes preferentially recognizing infected cells. Strikingly, a subset of TCRs recognized infected but not bystander macrophages. Antigen transfer occurred through soluble Mtb proteins rather than extracellular vesicles. Compared with responses to infected macrophages, bystander macrophages induced attenuated effector responses. These findings reveal antigen-specific recognition of bystander macrophages and suggest that antigens preferentially presented by infected cells may inform TB vaccine design.

  • Open Access

    BCG vaccination elicits protection against M. tuberculosis infection mediated by two phases of T cell immunity

    by Abiola F. Ogunsola, Rocky Lai, Kelly Cavallo, Anthony V. Tran, Gillian L. Beamer, Samuel M. Behar

    Vaccine development for tuberculosis (TB) is a global priority. Our studies using Collaborative Cross (CC) mice show that genetic diversity influences the efficacy of BCG, the most widely used TB vaccine. BCG vaccination of CC042 mice reduced their lung bacillary burden and increased their survival following low-dose aerosol Mycobacterium tuberculosis infection (MTBI), despite impaired T cell trafficking due to a defective Itgal gene. BCG vaccination conferred early bacillary control that appeared to be independent of B cell or T cell recall responses following MTBI. In contrast, long-term survival of BCG-vaccinated CC042 mice after MTBI required T cells. Thus, CC042 mice reveal two phases of immunity induced by BCG: an early phase mediated by innate immunity or innate-like T cells and a later phase mediated by conventional memory CD4 + and/or CD8 + T cells. Although measurement of vaccine-induced protection 30 days after MTBI is a standard measure of vaccine efficacy in the TB model, this time point might be independent of memory T cells in CC042 mice. Our results suggest that vaccine-elicited innate/innate-like responses could have a larger role in protection than previously considered. The concordance between lung CFU, pathology, and survival makes CC042 mice useful for mechanistic studies on vaccine-induced immunity.


  • Open Access

    Genetically diverse CC and DO mouse models enable comprehensive assessments of novel tuberculosis vaccines

    by Rocky Lai, Sherry L. Kurtz, Victoria Gould, Anthony Tran, Sam Afkhami, Roland Brosch, Cecilia S. Lindestam Arlehamn, Zhou Xing, Karen L. Elkins, Samuel M. Behar

    Development of a new vaccine for tuberculosis (TB) to replace the BCG vaccine has been hampered by the lack of a preclinical vaccine model that accurately reflects the genetic heterogeneity of the human population. We previously tested both Collaborative Cross (CC) and Diversity Outbred (DO) mice, which collectively reflect the genetic diversity of an outbred population, as models for preclinical vaccine testing. Using both CC and DO mice, we compared the ability of two different strategies to enhance BCG-mediated protection against Mycobacterium tuberculosis (Mtb). BCG::ESX-1Mmar is genetically modified to express the esx-1 region of Mycobacterium marinum. In contrast, the BCG/ChAd:TB strategy relies on boosting BCG-induced immunity using a chimp adenoviral vectored vaccine expressing the mycobacterial antigens Ag85A, TB10.4, and RpfB administered by the intranasal route. Both BCG::ESX-1Mmar and BCG/ChAd:TB vaccination strategies significantly protect mouse strains that were not well protected by BCG. Although both vaccination strategies were associated with reduced bacterial growth in CC and DO mice, bacterial control did not correlate with survival. Both BCG::ESX-1Mmar and BCG/ChAd:TB induced immune signatures after Mtb challenge in the tested CC strains that were previously associated with protection in traditional inbred mouse strains. Our findings established the use of both CC and DO mice as robust platforms that incorporate host genetic diversity for the preclinical evaluation of TB vaccines.

  • Open Access

    immgenT CD4: a reference landscape of mouse CD4 + T cells

    by Nitya Mehrotra, Derek Bangs, Andrea Lebron Figueroa, Gavyn Chern Wei Bee, Rocky Lai, Tomoyo Shinkawa, Kevin C. Osum, Antoine Freuchet, Ziang Zhang, Lilian Nogueira, et al.

    CD4⁺ T cells are orchestrators of the immune system with diverse effector functions. Their full molecular diversity remains unclear due to the lack of a unified framework. Within the immgenT project, we profiled RNA, surface markers, and TCR clonotypes in conventional CD4⁺T cells across >700 samples. Integration with a joint RNA–protein deep generative model revealed an ensemble of 20 CD4 states that account for all cells across tissues and challenges. Small, highly polarized clusters (“tips”) that evoke Th1, Th2, Th17, and Tfh states co-exist with a majority of activated cells with mixed programs occupying “midland” states. Unlike CD8⁺ T cells, memory CD4⁺ cells largely mapped to the same states as effectors. Resting states proved quite diverse, and we uncovered unexpected similarities between Tfh and chronically-stimulated states. Together, immgenT provides a unified molecular reference for CD4⁺ T cell diversity.


  • Open Access

    The CD8 + immgenT framework as a universal reference of mouse CD8αβ T cell differentiation states

    by Giovanni Galletti, Anna-Maria Globig, Olga Barreiro, Taylor A. Heim, Shuozhi Liu, Samantha M. Borys, Odhran Casey, Alexander Troy Monell, Dhruv Patravali, Nicole E. Scharping, et al.

    Mouse CD8 + T cell differentiation has been studied extensively in models of infections and tumors, yet no unified framework spans the full spectrum of immunological contexts. Within the immgenT project, we profiled RNA, surface markers, and TCR clonotypes in conventional CD8 + T cells across >600 samples, spanning multiple perturbations, tissues, and timepoints. Twenty-one clusters across naive, effector, circulating memory, tissue-resident memory, progenitor-exhausted, and terminally exhausted CD8 + T cell compartments emerged, with striking molecular convergence across acute and chronic infections, tumors, autoimmunity, aging, and homeostasis, illustrating that shared transcriptional states support protective or dysfunctional outcomes depending on developmental history and microenvironment. We validate this framework by integrating external datasets from conditions not represented in immgenT and by defining a flow cytometry panel spanning the CD8 + landscape. Thus, immgenT-CD8 provides a molecular framework harmonizing fragmented CD8 + T cell literature and clarifies relationships across diverse immune challenges.


  • Open Access

    Type I interferon–driven lung pathology restricts T cell accumulation and motility during tuberculosis

    by Maxime Caouaille, Léa Fromont, Tomoyo Shinkawa, Marion Faucher, Aizat Iman Abdul Hamid, Annie Behar, Serge Mazères, Yaël Duvergé, Emeline Decarpentrie, Yohan Lorreyte, et al.

    CD8 + T cells are elicited during tuberculosis yet how susceptible lung environments shape their maintenance and behavior is unclear. We examined pulmonary T cell responses to Mycobacterium tuberculosis in resistant control and Sp140 -/- mice, a model of type I interferon (IFN-I)-driven susceptibility. Resistant mice generated diverse CD8 + effector- and memory-like subsets producing TNF and IFNγ, whereas Sp140 -/- mice showed a broad loss of pulmonary CD8 + T cells. Single-cell RNA sequencing revealed altered states in CD8 + T cells from susceptible mice with exhaustion and IFN-I transcriptional programs. IFNAR blockade rescued CD8 + T cell numbers, diversity, cytokine production, reduced bacterial burden and lung pathology, with comparable benefits also valid for CD4 + T cells. Intravital microscopy of infected lungs further showed that T cell dynamics and motility within lesions were restricted under exuberant IFN-I signaling but fully restored by IFNAR blockade. Thus, IFN-I-driven tissue pathology restricts T cell accumulation and motility during tuberculosis. Teaser: In tuberculosis, excessive type I interferon signaling reshapes the lung environment, limiting T cell accumulation and motility within infected lesions.


  • Open Access

    BCG vaccination elicits protection against Mtb infection mediated by two phases of T cell immunity

    by Abiola F. Ogunsola, Rocky Lai, Kelly Cavallo, Gillian L. Beamer, Samuel M. Behar

    /Summary: Vaccine development for tuberculosis is a global priority. Our studies using Collaborative Cross (CC) mice show that genetic diversity influences the efficacy of BCG, the most widely used TB vaccine. BCG vaccination of CC042 mice reduces their lung bacillary burden and increases their survival following low-dose aerosol Mycobacterium tuberculosis infection (MTBI), despite impaired T cell trafficking from a defective Itgal gene. Early protection requires the presence of T cells at the time of BCG vaccination but is not mediated by B cell or T cell recall responses following MTBI. In contrast, T cell depletion following BCG vaccination reduces survival after MTBI. Thus, CC042 mice reveal two phases of immunity induced by BCG that require T cells: an early phase mediated by innate responses and a later phase mediated by effector CD4 and/or CD8 T cells. Although measurement of vaccine-induced protection 30 days after MTBI is a standard measure of vaccine efficacy in the murine TB model, we find this time point is independent of memory T cells. Our results suggest that vaccine-elicited innate responses have a larger role in protection than previously considered. The concordance between lung CFU, pathology, and survival make CC042 mice a useful model for vaccine evaluation.

  • Open Access

    CD226 identifies effector CD8+ T cells during tuberculosis and costimulates recognition of Mycobacterium tuberculosis-infected macrophages

    by Tomoyo Shinkawa, Evelyn Chang, Tasfia Rakib, Kelly Cavallo, Rocky Lai, Samuel M. Behar


  • Open Access

    NRF2 inhibition of alveolar macrophage MHC II expression during Mycobacterium tuberculosis infection

    by Linh K. Pham, Maritza M. Cervantes, Pamelia N. Lim, Divya Dubey, Ankita Tufts, Tomoyo Shinkawa, Samuel M. Behar, Alissa C. Rothchild

    SUMMARY: During Mycobacterium tuberculosis (Mtb) infection, infected alveolar macrophages (AMs) initially up-regulate a NRF2 regulated cell-protective program, which is detrimental to host control and impedes AM activation, including MHC II expression. MHC II is critical for CD4 + T cell activation and host immunity during Mtb infection. We hypothesized that NRF2 regulates the MHC II pathway and AM antigen presentation to T cells. We found that NRF2 inhibits MHC II, but not MHC I, specifically in AMs, following Mtb infection in vitro and in vivo . NRF2 dampens Ciita and H2-Ab1 gene expression in uninfected AMs, and MHC II inhibition by NRF2 is retained following innate stimuli and IFNγ exposure. NRF2 expression in Mtb-infected AMs impedes their ability to activate ESAT6-specific CD4 + T cells. Thus, although NRF2 expression enhances cell-protective functions, it has the unexpected consequence of limiting innate-adaptive crosstalk, which can impair CD4+ T cell activation and host immunity during Mtb infection. HIGHLIGHTS: NRF2 inhibits MHC II on AMs, but not DCs, MDMs, or PMNs, during Mtb infection NRF2 inhibits Ciita and H2-Ab1 and total MHC II protein in AMs, but not in BMDMs NRF2 blockade of AM MHC II is retained following PAMP and IFNγ stimulation NRF2 impedes the activation of antigen-specific CD4 + T cells by Ams


  • Top Cited Papers

    Finding and filling the knowledge gaps in mechanisms of T cell-mediated TB immunity to inform vaccine design

    by Emma Lefrançais, Denis Hudrisier, Olivier Neyrolles, Samuel M. Behar, Joel D. Ernst

    Mycobacterium tuberculosis, the bacterium that causes tuberculosis (TB), results in more human mortality than any other single pathogen, in part because of the lack of an effective vaccine. Although T cells are essential for immunity to TB, the mechanisms that provide protective immunity are poorly understood. In this Review, we describe current gaps in our knowledge about T cell-mediated immune responses to M. tuberculosis and discuss how recent technologies, including multiphoton intravital microscopy, spatial multiomics and high-resolution in vivo analyses of cell–cell interactions, may be used to gain insights that can inform the design of T cell-targeted TB vaccines.